UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of oncology, 2023-03, Vol.34 (3), p.228-246

2023

Volltextzugriff (PDF)

Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia

Leukemia, 2015-06, Vol.29 (6), p.1243-1252

2015

Volltextzugriff (PDF)

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

Leukemia, 2017-10, Vol.31 (10), p.2020-2028

2017

Volltextzugriff (PDF)

Karyotype complexity and prognosis in acute myeloid leukemia

Blood cancer journal (New York), 2016-01, Vol.6 (1), p.e386-e386

2016

Volltextzugriff (PDF)

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

Blood cancer journal (New York), 2016-07, Vol.6 (7), p.e449-e449

2016

Volltextzugriff (PDF)

Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia

Leukemia, 2016-04, Vol.30 (4), p.782-788

2016

Volltextzugriff (PDF)

Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled on to the CUPISCO study

ESMO open, 2023-12, Vol.8 (6), p.102035-102035, Article 102035

2023

Volltextzugriff (PDF)

Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay

European journal of cancer (1990), 2016-12, Vol.69, p.S55-S55

2016

Volltextzugriff (PDF)

Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders

Leukemia, 2012-04, Vol.26 (4), p.728-735

2012

Volltextzugriff (PDF)

174P Frequency and prognostic value of circulating tumor cells in cancer of unknown primary

Annals of oncology, 2023-10, Vol.34, p.S250-S251

2023

Volltextzugriff (PDF)

Diagnostik und Therapie von Krebserkrankungen mit unbekanntem Primärtumor (CUP-Syndrom)

Best practice onkologie, 2020-03, Vol.15 (3), p.76-84

2020

Volltextzugriff (PDF)

519P Patterns of care and outcomes in carcinoma of unknown primary: A SEER-Medicare study

Annals of oncology, 2020-09, Vol.31, p.S459-S459

2020

Volltextzugriff (PDF)

738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trial

Annals of oncology, 2022-09, Vol.33, p.S881

2022

Volltextzugriff (PDF)

1804P Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO

Annals of oncology, 2021-09, Vol.32, p.S1227-S1228

2021

Volltextzugriff (PDF)

Chronic lymphocytic leukaemia and concomitant relapsing polychondritis: a report on one treatment for the combined manifestation of two diseases

Rheumatology (Oxford, England), 2005-09, Vol.44 (9), p.1199-1199

2005

Volltextzugriff (PDF)

2037PA challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

2037P - A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience

Annals of oncology, 2019-10, Vol.30, p.v813-v814

2019

Volltextzugriff (PDF)

A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience

Annals of oncology, 2019-10, Vol.30, p.v813-v814

2019

Volltextzugriff (PDF)

Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC

Annals of oncology, 2019-10, Vol.30, p.v631-v632

2019

Volltextzugriff (PDF)

1538PReal-world implementation of sequential targeted therapies for EGFR-mutated NSCLC

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1538P - Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC

Annals of oncology, 2019-10, Vol.30, p.v631-v632

2019

Volltextzugriff (PDF)

152 - Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay

European journal of cancer (1990), 2016-12, Vol.69, p.S55-S55

2016

Volltextzugriff (PDF)

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

Blood advances, 2018-01, Vol.2 (1), p.1-9

2018

Volltextzugriff (PDF)

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis

Haematologica (Roma), 2008-03, Vol.93 (3), p.459-462

2008

Volltextzugriff (PDF)

Systemische Leichtketten-Amyloidose – Molekulare Grundlagen und klinische Perspektiven

Deutsche medizinische Wochenschrift, 2009-09, Vol.134 (39), p.1949-1952

2009

Volltextzugriff (PDF)

1 – 25 von 374

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(333)
Mit Volltextzugriff
(319)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(368)
Japanisch
(28)
Deutsch
(7)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo

Karyotype complexity and prognosis in acute myeloid leukemia

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia

Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia

Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled on to the CUPISCO study

Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay

Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders

174P Frequency and prognostic value of circulating tumor cells in cancer of unknown primary

Diagnostik und Therapie von Krebserkrankungen mit unbekanntem Primärtumor (CUP-Syndrom)

519P Patterns of care and outcomes in carcinoma of unknown primary: A SEER-Medicare study

738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trial

1804P Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO

Chronic lymphocytic leukaemia and concomitant relapsing polychondritis: a report on one treatment for the combined manifestation of two diseases

2037PA challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience

2037P - A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience

A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: The CUPISCO trial experience

Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC

1538PReal-world implementation of sequential targeted therapies for EGFR-mutated NSCLC

1538P - Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC

152 - Identification of therapeutically targetable genomic alterations in a cohort of patients with CUP using a hybrid-capture based next generation sequencing assay

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma

Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis

Systemische Leichtketten-Amyloidose – Molekulare Grundlagen und klinische Perspektiven

Suchergebnisse filtern